VRDN Viridian Therapeutics, Inc.\DE: institutional ownership and insider trading
223 funds reported holding $2.70B of Viridian Therapeutics, Inc.\DE in their latest 13F filings; in Q2 2026 funds net bought $430M, with 44 new positions and 52 funds selling out; over the last 12 months insiders bought $20.0M and sold $419K on the open market.
Famous investors holding VRDN
- Renaissance Technologies (Renaissance Technologies): $14.1M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $21.7M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $3.89M, 0.0% of the portfolio
Largest institutional holders of VRDN
- FMR LLC — $305M
- VANGUARD GROUP INC — $175M
- BlackRock, Inc. (BLK) — $157M
- Bellevue Group AG — $124M
- Paradigm Biocapital Advisors LP — $124M
- Kynam Capital Management, LP — $119M
- STATE STREET CORP (STT, STT-PG) — $113M
- PRICE T ROWE ASSOCIATES INC /MD/ — $106M
- Fairmount Funds Management LLC — $93.5M
- VANGUARD CAPITAL MANAGEMENT LLC — $84.1M
Recent VRDN insider trades
- Aug 19, 2026: Tousignant Jennifer sold 14,212 shares ($348K)
- May 11, 2026: Fairmount Healthcare Fund II L.P. bought 1,176,470 shares ($20.0M)
- Dec 31, 2025: Tousignant Jennifer sold 2,272 shares ($70.8K)
- Oct 23, 2025: Fairmount Healthcare Fund II L.P. bought 454,545 shares ($10.00M)
5%+ owners
- Fairmount Funds Management LLC: 14.0% (Schedule 13D/A, filed May 13, 2026)
- Bellevue Group AG: 6.6% (Schedule 13G, filed May 15, 2026)
- Paradigm BioCapital Advisors LP: 6.1% (Schedule 13G/A, filed Aug 14, 2026)
- Kynam Capital Management, LP: 5.7% (Schedule 13G/A, filed Aug 14, 2026)
- STATE STREET CORPORATION: 5.5% (Schedule 13G, filed Aug 7, 2026)
- T. Rowe Price Associates, Inc.: 5.2% (Schedule 13G, filed Aug 14, 2026)